Reports Q4 revenue $307.1M, consensus $321.29M. “We closed out 2023 with strong revenue performance in the fourth quarter,” said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. “We are well-positioned for a successful 2024 with several potential exciting clinical and regulatory milestones ahead. We look forward to initiating the global regulatory submissions for sepiapterin for the treatment of PKU, which we see as a potential billion-dollar opportunity, as well as to advancing our PTC518, vatiquinone, and utreloxastat programs.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- SHAREHOLDER ALERT: Potential Recovery for PTC Therapeutics, Inc. (PTCT) Investors
- PTCT Earnings this Week: How Will it Perform?
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PTC Therapeutics put buyer realizes 42% same-day gains
Questions or Comments about the article? Write to editor@tipranks.com